Clark Wealth Partners’s Biogen BIIB Stock Holding History

Clark Wealth Partners’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.51K	Hold	7	–	–	﹤0.01%	447
2026 Q1	$1.28K	Hold	7	–	–	﹤0.01%	495
2025 Q4	$1.23K	Hold	7	–	–	﹤0.01%	472
2025 Q3	$1.23K	Hold	7	–	–	﹤0.01%	472
2025 Q2	$879	Buy	+7	New	+$872	﹤0.01%	449

Other funds holding BIIB

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Clark Wealth Partners's BIIB Position: Q2 2026 in Review

Clark Wealth Partners held its Biogen (BIIB) position steady in Q2 2026 at 7 shares worth $1.51K. The position accounts for ﹤0.01% of the portfolio, ranked #447.

Clark Wealth Partners first reported a position in BIIB in Q2 2025 and has held it in 5 quarters since. 981 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.

Clark Wealth Partners held 7 shares of Biogen worth $1.51K as of Q2 2026.
Clark Wealth Partners left its Biogen share count unchanged in Q2 2026.
Biogen made up ﹤0.01% of Clark Wealth Partners's portfolio in Q2 2026, its #447 holding.
Clark Wealth Partners first reported a position in Biogen in Q2 2025 and has held it in 5 quarters since.
981 funds tracked by Wall St. Rank held Biogen as of Q2 2026.

Based on Clark Wealth Partners's 13F filing for Q2 2026, filed 28 Jul 2026.